cor2ed
engage checkpoint medical linkedin twitter
bg

Adjuvant Therapy in mRCC

Adjuvant Therapy in mRCC

Prof. Sandy Srinivas

This month Prof. Sandy Srinivas and Dr. Roberto Iacovelli provide their thoughts and views on: Adjuvant Therapy in mRCC
Image of Sandy Srinivas
Prof. Sandy Srinivas

Medical Oncologist

Stanford University Medical Center

United States (US)

preview next

time | open 5 min | 2017

download resources

I agree that this educational programme:

Emerging treatments from multiple drug trials

Medical Oncologists, Prof. Sandy Srinivas and Dr. Roberto Iacovelli, discuss the use of adjuvant therapy in metastatic renal cell carcinoma (mRCC). Discussion centres on drug trials, in particular, comparison of the ASSURE trial and the S-TRAC TRIAL. The ASSURE trial is a study of VEGF receptor tyrosine kinase inhibitors, sorafenib and sunitinib, and examines disease free survival as a primary endpoint. The S-TRAC trial is a study of the effect of sunitinib in treatment of clear-cell RCC, looking at disease free survival and overall survival. Our experts explore the differences between these two studies and cover details of other trials including the PROTECT trial of Pazopanib treatment in clear-cell RCC, and several other trials pertinent to adjuvant therapy in kidney cancer. Please explore the slides and watch the video to gain the latest clinical insights on adjuvant therapy in mRCC.

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest